16 December 2013 - The IQWiG has completed its reassessment of vemurafenib (Zelboraf), a drug used to treat adults with a  certain type of advanced melanoma, after the Federal Joint Committee (G-BA) had limited its decision to an initial one year period. Roche, the manufacturer of vemurafenib, prepared and lodged a second dossier to the IQWIG. Although this dossier includes additional and more recent data, it essentially contains no new information. The IQWiG therefore continues to see an indication of a considerable added value in vemurafenib. [German]

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/vemurafenib_trotz_neuer_daten_kein_verandertes_ergebnis.5362.html?&et_cid=4&et_lid=%208